Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ibrutinib
Find trials that include:  Any drugs shown
Results 1-25 of 59 for your search:
Start Over
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1137-CA, NCI-2015-01722, NCT02436668
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Status: Enrolling by invitation
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR100955, NCI-2013-02262, 2012-004225-24, NCT01804686
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: UTX-IB-301, NCI-2015-00855, NCT02301156
Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A051301, NCI-2015-00668, BMT CTN 1201, NCT02443077
Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-006, NCI-2015-01966, NCT02477696
Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1119-CA, NCI-2014-00660, PCI-32765 [Sponsor], NCT01962792
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1123-CA, NCI-2014-00826, NCT02077166
Ibrutinib in Treating Patients with Refractory or Recurrent Primary or Secondary Central Nervous System Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-184, NCI-2014-02562, NCT02315326
Ibrutinib and Obinutuzumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and over
Trial IDs: GA101 + Ibrutinib, NCI-2015-02052, 141106, NCT02315768
Ibrutinib in Treating Patients with Recurrent or Stage IV Non-small Cell Lung Cancer with an EGFR Mutation
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0602, NCI-2015-00124, NCT02321540
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PCYC-1136-CA, NCI-2015-00777, NCT02401048
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PCYC-1135-CA, NCI-2015-00591, NCT02403271
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to less than 80
Trial IDs: CC-122-CLL-001, NCI-2015-01973, NCT02406742
Venetoclax in Combination with Obinutuzumab and Ibrutinib in Treating Patients with Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14266, NCI-2015-00252, ML29533, NCT02427451
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1138-CA, NCI-2015-01756, PCI-32765, NCT02548962
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1128-CA, NCI-2016-00449, NCT02599324
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MEDI4736-NHL-001, NCI-2016-00820, NCT02733042
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Status: Enrolling by invitation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1103-CA, NCI-2011-00986, PCI-32765, NCT01109069
Ibrutinib in Treating Patients with Relapsed Hairy Cell Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9268, NCI-2013-00826, 2012C0139, NCT01981512, OSU-12200, P131378, 14-C-0004, NCT01841723
Ibrutinib and Rituximab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma or Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0090, NCI-2013-01304, NCT01880567
Ibrutinib with or without Rituximab in Treating Patients with Relapsed Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0703, NCI-2014-00989, NCI-2014-00843, NCT02007044
Ibrutinib after Intensive Induction in Treating Patients with Previously Untreated Mantle Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14H06, NCI-2014-01777, PCI-32765MCL2003, STU00098385, NCT02242097
Ibrutinib in Treating Patients with Newly Diagnosed B-cell Lymphoma in First Complete Remission after Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0096, NCI-2015-00843, NCT02272686
A Multicenter Open-Label Phase 2a Study of Ibrutinib Monotherapy or in Combination With Either Cytarabine or Azacitidine in Subjects With Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1131-CA, NCI-2015-00202, NCT02351037
Ibrutinib in Treating Patients with Advanced Systemic Mastocytosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HEMMPD0021, NCI-2014-02341, NCT02415608
Start Over